Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4070
-0.0270 (-6.22%)
At close: Mar 13, 2026, 4:00 PM EDT
0.4035
-0.0035 (-0.86%)
After-hours: Mar 13, 2026, 7:54 PM EDT
Ensysce Biosciences Employees
As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$560,997
Profits / Employee
-$1,371,559
Market Cap
1.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | 3 | - | - | 3 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Aditxt | 26 |
| Dermata Therapeutics | 8 |
| CNS Pharmaceuticals | 5 |
| Onconetix | 5 |
| OKYO Pharma | 4 |
ENSC News
- 11 days ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
- 12 days ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
- 16 days ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 18 days ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 20 days ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
- 6 weeks ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 7 weeks ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
- 2 months ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire